High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma

W-F Cheng1,2,3, C-Y Huang2,3, M-C Chang2,3, Y-H Hu2,3, Y-C Chiang2,3, Y-L Chen2,3, C-Y Hsieh2,3 and C-A Chen2,3

1Graduate Institute of Clinical Medicine, Taipei, Taiwan; 2Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei, Taiwan; 3Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan

The objective of this paper is to investigate the mesothelin expression level to the clinicopathological features, chemoresponse, and to the outcome of patients with epithelial ovarian carcinoma (EOC). Mesothelin mRNA was detected by real-time quantitative reverse-transcription PCR in 139 EOC patients. Clinical characteristics, histopathological items, responses to chemotherapy, progression-free survival (PFS), and overall survival (OS) were recorded. Tumours with advanced stages had higher mesothelin than those with early stages. The chemoresistant patients showed significantly higher mesothelin than did chemosensitive patients (2.81 vs 0.43, P<0.001), irrespective of optimal or suboptimal surgery in those with advanced stages. Highly expressed levels of mesothelin were an independent but poor prognostic factor in the PFS (2.03 (1.23–3.37) P = 0.006) and OS (3.72 (1.64–8.45), P = 0.002) of the 139 EOC patients in multivariate analysis. In addition, patients in advanced stages with highly expressed mesothelin also had significantly worse OS, regardless of whether they had undergone optimal (13.85 (1.76–125.60), P = 0.013) or suboptimal (4.47 (1.83–10.88), P = 0.001) debulking surgery in multivariate analysis. Our results provide new evidence that mesothelin expression is associated with chemoresistance and with shorter disease-free survival and worse OS of patients with EOC.

Keywords: epithelial ovarian carcinoma; mesothelin; chemotherapy; drug resistance

Ovarian cancer, especially epithelial ovarian carcinoma (EOC), has become an extremely important disease in recent years because it has the highest mortality rate of all gynaecological malignancies (Parkin et al, 1993; Beard et al, 2000; Boyle et al, 2000). Around 75% of patients are diagnosed at an advanced stage (Pfleiderer, 1984), and the overall survival (OS) rates of these patients are only 19–30% (Pfleiderer, 1984; Gonzalez-Diego et al, 2000). The standard treatment of EOC is surgical tumour debulking, followed by chemotherapy (Agarwal and Kaye, 2003; DiSaia and Bloss, 2003). Administration of adjuvant chemotherapy, consisting of a platinum compound (cisplatin or carboplatin), remains the standard treatment after surgery even in the early stages of EOC (DiSaia and Bloss, 2003; Schwartz, 2003; Sturt, 2003).

Platinum, combined with cyclophosphamide- or taxane-based chemotherapy, is the most common cytotoxic regimen for adjuvant chemotherapy of EOC patients (Rustin et al, 1996). Platinum-based chemotherapy, given at 3-week intervals for a total of three to six cycles, produces around 80% response rate in all stages of ovarian cancer (Greenlee et al, 2001). However, 50–70% of patients relapse and ultimately die from their cancer circumstances (Ozols, 2002). As resistance to chemotherapeutic drugs plays a major role in tumour progression (Bradshaw and Arceci, 1998; Haq and Zanke, 1998), the identification of patients who are resistant to platinum-based chemotherapy will allow the choice of cytotoxic drugs of other mechanisms, the development of novel drugs, and new therapeutic strategies.

Mesothelin is a glycoprotein to be largely restricted to mesothelial cells or to epithelial cells of the trachea, tonsils, fallopian tube, and kidneys (Chang et al, 1992). Mesothelin has been reported as a tumour-associated marker in several types of human cancers, including ovarian carcinomas and adenosarcomas arising from the pancreato-biliary tract, endometrium, and lungs (Chang et al, 1992). Mesothelin has also been reported to interact with CA125 to mediate cell adhesion (Rump et al, 2004). Although the biological functions of mesothelin remain largely unknown (Bera and Pastan, 2000), there is evidence that mesothelin has the potential as a new cancer biomarker (Cheng et al, 2007) and as a target molecule for gene therapy (Chang et al, 2007). Some investigators have reported that mesothelin can be a new marker for the diagnosis of ovarian carcinoma (Huang et al, 2006; Yen et al, 2006) and as a target in mesothelin-expressing tumours (Fan et al, 2002; Hassan et al, 2007a, b).

Although mesothelin has been documented as a tumour-associated marker in EOC, analyses focusing on the correlation between mesothelin expression and clinicopathological variables and clinical outcomes have seldom been carried out. The purpose of this study is to use real-time quantitative reverse-transcription (RT)–PCR to assess the clinical significance of mesothelin expression in EOC patients.
MATERIALS AND METHODS

Patients and specimens

From July 1994 to June 2008, 139 patients with ovarian epithelial carcinoma undergoing staging or debulking surgery were enrolled. The experimental protocols were reviewed and approved by the Institutional Review Board of the National Taiwan University Hospital. Cancerous tissues were acquired after informed consent was signed. After surgical staging with debulking surgery, early- or advanced-stage patients, except those with stage IA and grade I disease, received four or six courses of adjuvant chemotherapy with platinum plus cyclophosphamide or paclitaxel regimens. The histological grading was according to the International Union against Cancer criteria (Sobin and Fleming, 1997), whereas staging was according to the criteria set by the International Federation of Gynecology and Obstetrics.

Pre-existing clinical information, including age, menopausal status, clinical stage, treatment history, surgical findings during debulking, recurrence status, and survivorship, was collected from clinical and operative notes and discharge summary that were deposited in a centralised database. The maximal diameter of the residual tumour during surgery was also recorded. Optimal debulking surgery was defined as the maximal diameter of residual tumour <1 cm or otherwise defined as suboptimal debulking surgery. Patients received regular follow-up after completion of treatment. Computerised tomography or magnetic resonance imaging was carried out when recurrence was suspected. Abnormal results of imaging studies, aspiration cytology from ascites, elevated tumour markers (≥2-fold of upper normal limits) of two consecutive tests at 2-week intervals, or tissue proven from biopsy, if possible, were defined as recurrence. Progression-free survival (PFS) was measured as the period from operation to the date of confirmed recurrence or disease progression, or to the date of the investigators’ last note of a disease-free status. Patients with disease progression or with disease recurrence ≤6 months after discontinuing chemotherapy were defined as chemoresistant, whereas those without recurrence or with recurrence >6 months after discontinuing chemotherapy were defined as chemosensitive.

Extraction of RNA in ovarian cancer tissues

Cancerous tissue specimen was collected during surgery, was immediately frozen in liquid nitrogen, and stored at −70°C until analysis. The total RNA of ovarian cancer tissues was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s instructions.

Real-time quantitative RT–PCR

Mesothelin and G6PDH RNA were first reverse transcribed to cDNA. Real-time PCR was carried out using the LightCycler Real-Time detection system (Roche Diagnostics, Mannheim, Germany), according to the manufacturer’s protocol, for 50 cycles of 10 s at 95°C, 10 s at 60°C, and 10 s at 72°C. 5'-CTATTCCTCAACCCAGATGGT and 3'-GCACATCAGCCTCGCTCA were the primers used to detect mesothelin. The detection of G6PDH was carried out by the LightCycler h-G6PDH housekeeping gene set (Roche Applied Science, Indianapolis, CA-3’ and 5’-CTCATCACACCTCTGCTACCCAG-3’, for 30 cycles was used. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the housekeeping gene to compare with our target gene, mesothelin. For the generation of GAPDH, a set of primers, 5'-ACCCAGAGCAGCTGGG-3’ and 5'-GCTGTAGCCAAA TTCGTTG-3’, for 23 cycles was also used.

The products of PCR were then analysed in 1% agarose gel with ethidium bromide staining in TBE solution. PCR products of around 440 and 520 bp were regarded as exact products and periodic DNA sequencing was carried out to confirm whether the PCR products were exact. The gel images were then obtained by using a CCD camera (Biocapt company, Vilibour Lornart, Marne la Vallée, France) and the bands of interest were stored as TIFF files using BioCapt software as described earlier (Masson et al, 2001). The density of mesothelin/density of GAPDH was regarded as the expression level of mesothelin in each ovarian cancer tissue.

Statistical analysis and clinical correlation

Statistical analyses were carried out with the Statistical Package of Social Studies (SPSS) version 8.0 (SPSS Inc., Chicago, IL, USA) for Windows. Comparisons between unpaired groups were made using the Mann–Whitney U test, one-way analysis of variance (ANOVA), Student’s t-test, the χ² test, and the Kruskal–Wallis H test. Spearman’s correlation was used to determine the association between RTQ RT–PCR and semi-quantitative RT–PCR (SQ RT–PCR) values in mesothelin expression. Serum CA125 and mesothelin expression levels were first assessed as continuous variables and analysed using the Mann–Whitney U test and the Kruskal–Wallis H test. The serum CA125 and mesothelin expression levels were further assessed as categorical variables. The values of serum CA125 were divided at 1000 U/ml and the values of mesothelin expression levels >1 after an earlier calculation were defined as highly expressed and those <1 as low expressed for the survival analyses. Survival curves were generated using the Kaplan–Meier method and differences in survival curves were calculated using the log rank test. Cox’s univariate and multivariate regression analyses were used to evaluate the prognostic factors for PFS and OS survival. A P-value less than 0.05 was considered statistically significant.

RESULTS

The clinicopathological items between the chemosensitive and chemoresistant groups were also shown in Table 1. Chemoresistant patients were older, had larger amounts of ascites, higher percentage of advanced stages, and higher incidence of suboptimal debulking surgery than did chemosensitive patients. However, the number of gravida and parity, status of menopause, histological types, tumour histological grading, lymph node metastasis, and...
Mesothelin with chemoresponse of epithelial ovarian carcinoma

W-F Cheng et al

Table 1 The summary of the patient characteristics, preoperative median serum levels of CA125, and expression levels of mesothelin in 87 chemosensitive and 52 resistant ovarian epithelial cancer patients.

| Patient number | Total population | Chemosensitive | Chemoresistant | P-value |
|----------------|------------------|----------------|----------------|---------|
| Age (mean ± s.d.) | 54.7 ± 11.9 | 52.7 ± 11.2 | 57.9 ± 12.3 | 0.015* |
| Gravida | 3.2 ± 2.5 | 2.7 ± 2.5 | 3.7 ± 2.4 | 0.34* |
| Parity | 2.2 ± 1.8 | 1.9 ± 1.6 | 2.5 ± 1.8 | 0.43* |
| Tumour size (cm) | 10.9 ± 5.8 | 11.9 ± 6.1 | 9.3 ± 5.1 | 0.008* |
| Asceses (ml) | Median (25th to 75th percentile) | 500 (50–2500) | 300 (50–1800) | 1050 (100–3600) | 0.013* |
| Menopause | Yes | 83 (60%) | 50 | 33 | 0.49* |
| No | 56 (40%) | 37 | 19 |
| Histology | Serous | 86 (62%) | 51 | 35 | 0.31* |
| Non-serous | 53 (38%) | 36 | 17 |
| Grade | Early (I and II) | 35 (25%) | 30 | 5 | 0.001* |
| Advanced (III and IV) | 104 (75%) | 57 | 47 |
| Debulking surgery | Optimal | 78 (56%) | 60 | 18 | <0.001* |
| Suboptimal | 61 (44%) | 27 | 34 |
| Lymph node metastasis | Yes | 30 (39%) | 17 | 13 | 0.25* |
| No | 46 (61%) | 32 | 14 |
| CA125 (U/ml⁻¹) | Median (25th to 75th percentile) | 1046 (265–2560) | 899 (253–2344) | 1320 (456–4770) | 0.059* |

*Student’s t-test, †Mann–Whitney U test, ‡x² test between chemosensitive and chemoresistant groups.

pre-operative serum CA125 levels were not different between the two groups.

The clinicopathological features and pre-operative CA125 serum levels of the enrolled patients are shown in Table 2. The median age was 54 years (range: 28–80 years) at the time of diagnosis. The median duration of follow-up was 21 months (range: 1–102 months) and median disease-free interval was 11 months (range: 0–80 months), with 54 and 25 patients having recurrent and persistent diseases, respectively. Thirty-nine (28.1%) died, 31 (22.3%) lived with the disease, and 69 (49.6%) were disease free. Patients with serous, endometrioid, or mixed histological types, with advanced stages, and with suboptimal debulking surgery had significantly higher pre-operative serum levels of CA125 as compared with those with mucinous or clear cell histological type, with early stages, and with optimal debulking surgery.

The representative figures of RTQ RT–PCR for mesothelin (Figure 1A), RTQ RT–PCR for G6PD (Figure 1B), and SQ RT–PCR for mesothelin and GAPDH (Figure 1C) mRNA expressions are shown to evaluate the expression of mesothelin in cancerous tissues. Correlations between RTQ RT–PCR and SQ RT–PCR values for the expression of mesothelin are significantly high in this survey (r = 0.334, P < 0.001, Spearman’s correlation) (Figure 1D).

The relationships between clinicopathological items and expression levels of mesothelin were further evaluated. Patients with advanced stages (stage I: 0.31 (95% CI 0.08–1.52), stage II: 0.67 (95% CI 0.12–1.67), stage III: 1.52 (95% CI 0.33–3.35), stage IV: 2.60 (95% CI 0.94–4.96), P = 0.005), with high histological grade (poorly differentiated) (grade 1: 0.65 (95% CI 0.04–1.24), grade 2: 0.65 (95% CI 0.05–2.81), grade 3: 1.65 (95% CI 0.43–3.39), P = 0.015), and with suboptimal debulking surgery (optimal: 0.92 (95% CI 0.12–2.71), suboptimal: 1.54 (95% CI 0.55–4.35), P = 0.021) had significantly higher mesothelin as compared with those with early stages, lower histological grades, and with optimal debulking surgery (Table 2). Figure 2A showed the expression levels of mesothelin in different stages.

The chemoresistant patients showed significantly higher mesothelin than the chemosensitive patients (2.81 (95% CI 1.16–4.96) vs 0.43 (95% CI 0.06–2.13), P < 0.001). We then divided the patients into four subgroups, such as patients without recurrence or with recurrence >12 months after chemotherapy (n = 49), those with recurrence within 6–12 months after chemotherapy (n = 38), those with recurrence <6 months after chemotherapy (n = 27), and those with persistent disease (n = 25). As shown in Figure 2B, the mesothelin in the group with persistent disease and with recurrence <6 months after chemotherapy was significantly higher than that in patients with recurrence within 7–12 months after chemotherapy, and without recurrence or with recurrence >12 months after chemotherapy (P < 0.001, one-way ANOVA). However, the mesothelin expression was not different between groups of patients without recurrence or with recurrence longer than 12 months after chemotherapy and between patients with recurrence within 6–12 months after chemotherapy (P > 0.05, one-way ANOVA).

As advanced stages and residual tumour volume have been shown to correlate with the chemoresponse of EOC patients, there...
Table 2  The clinico-pathological items, preoperative median serum levels of CA125, and mesothelin expression levels in 139 ovarian epithelial carcinoma patients

| Items                  | Total population (n = 139) | Chemosensitive group (n = 87) | Chemoresistant group (n = 52) | Mesothelin expression level (median (25 – 75%)) | P-value | Chemosensitive group (n = 87) | Chemoresistant group (n = 52) |
|------------------------|----------------------------|-------------------------------|------------------------------|-----------------------------------------------|---------|-------------------------------|-------------------------------|
|                        | Number (%)                 | Number (%)                   | Number (%)                   | P-value                                       |         | Number (%)                   | P-value                       |
| **Histology**          |                            |                               |                               |                                               |         |                               |                               |
| Serous                 | 86 (61%)                   | 51 (59%)                      | 35 (67%)                     | 1.54 (0.36 – 3.16)                             | <0.001^a| 51 (59%)                      | 0.65 (0.07 – 2.39)            | 0.24^b                         |
| Mucinous               | 6 (4%)                     | 5 (65%)                       | 1 (2%)                       | 0.93 (0.29 – 2.13)                             |         | 5 (60%)                      | 0.92 (0.04 – 2.13)            | 6 (4%)                         |
| Endometrioid           | 17 (12%)                   | 12 (13%)                      | 5 (10.0%)                    | 0.73 (0.01 – 2.52)                             |         | 12 (13%)                     | 0.09 (0.01 – 1.01)            | 17 (12%)                       |
| Clear cell             | 21 (15%)                   | 13 (15%)                      | 8 (15%)                      | 1.04 (0.22 – 2.96)                             |         | 13 (15%)                     | 0.40 (0.11 – 2.96)            | 21 (15%)                       |
| Mixed                  | 8 (6%)                     | 6 (73%)                       | 2 (2%)                       | 0.25 (0.05 – 2.88)                             |         | 6 (7%)                       | 0.10 (0.02 – 0.58)            | 8 (6%)                         |
| Undifferentated        | 1 (1%)                     | 2 (4%)                        | 2 (4%)                       | 0.96                                           |         | 1 (1%)                       | 4.96                          |                               |
| **FIGO stage**         |                            |                               |                               |                                               |         |                               |                               |
| I                      | 25 (18%)                   | 24 (27%)                      | 1 (2%)                       | 0.31 (0.08 – 1.52)                             | 0.005^a | 24 (27%)                     | 0.22 (0.08 – 1.58)            | 0.24^b                         |
| II                     | 10 (7%)                    | 6 (73%)                       | 4 (8%)                       | 0.67 (0.12 – 1.67)                             |         | 6 (73%)                      | 0.12 (0.10 – 1.14)            | 4 (8%)                         |
| III                    | 85 (61%)                   | 49 (57%)                      | 36 (69%)                     | 1.52 (0.31 – 3.35)                             |         | 49 (57%)                     | 0.58 (0.36 – 2.17)            | 36 (69%)                       |
| IV                     | 19 (14%)                   | 8 (9%)                        | 11 (21%)                     | 2.60 (0.94 – 4.96)                             |         | 8 (9%)                       | 1.18 (0.39 – 6.40)            | 11 (21%)                       |
| **Tumour grading**    |                            |                               |                               |                                               |         |                               |                               |
| I                      | 19 (14%)                   | 14 (10%)                      | 5 (10%)                      | 0.65 (0.14 – 2.14)                             | 0.015^a | 14 (16%)                     | 0.12 (0.01 – 0.74)            | 0.002^b                        |
| II                     | 28 (20%)                   | 20 (23%)                      | 8 (15%)                      | 0.65 (0.05 – 2.81)                             |         | 20 (23%)                     | 0.16 (0.06 – 1.12)            | 8 (15%)                        |
| III                    | 92 (66%)                   | 53 (61%)                      | 39 (75%)                     | 1.65 (0.41 – 3.39)                             |         | 53 (61%)                     | 1.11 (0.13 – 2.80)            | 39 (75%)                       |
| **Optimal surgery**   |                            |                               |                               |                                               |         |                               |                               |
| Yes                    | 78 (56%)                   | 60 (89%)                      | 38 (57%)                     | 0.92 (0.12 – 2.71)                             | 0.02^b  | 60 (89%)                     | 0.47 (0.07 – 2.14)            | 0.95^b                         |
| No                     | 61 (44%)                   | 27 (31%)                      | 24 (35%)                     | 1.54 (0.55 – 4.35)                             |         | 27 (31%)                     | 0.34 (0.06 – 1.97)            | 34 (65%)                       |
| **Chemoresponse**      |                            |                               |                               |                                               |         |                               |                               |
| Sensitive              | 87 (63%)                   | NA                            | NA                           | 0.43 (0.06 – 2.13)                             | <0.001^b| NA                            | NA                           | NA                            |
| Resistant              | 52 (37%)                   | 1120 (45 – 470)               | 2.81 (1.16 – 4.96)           |                                               |         | 2.81 (1.16 – 4.96)           |                               |                               |

Abbreviation: NA = not available. ^aKruskal – Wallis H test. ^bMann – Whitney U test.
was additional focus on the 104 advanced-stage patients, who were divided into two groups – those with and those without optimal debulking surgery – to evaluate the correlations between mesothelin expression and chemoresponse. The chemoresistant group showed significantly higher mesothelin than did the chemosensitive group, regardless of optimal \( (n = 44) \) (2.99 vs 1.17, \( P < 0.001 \)) or suboptimal \( (n = 60) \) (3.12 vs 0.34, \( P < 0.001 \)) debulking surgery (Figure 2C).

Probable factors in clinicopathological parameters and biomarkers were further calculated to predict OS. As shown in Table 4, the stage (stages III/IV vs I/II, 2.08 (1.24–3.50), \( P = 0.006 \)) (Figure 3A), optimal debulking surgery (no vs yes, 3.35 (1.71–6.54), \( P < 0.001 \)) (Figure 3B), time to normal CA125 level cut-off within 63 days (longer vs less, 3.41 (1.80–6.47), \( P < 0.001 \)) (Figure 3C), and expression levels of mesothelin (high vs normal, 4.64 (2.15–10.03), \( P < 0.001 \)) (Figure 3D) showed significantly shorter OS by univariate analysis. However, highly expressed mesothelin (3.72 (1.64–8.45), \( P = 0.002 \)) was the only independent and poor prognostic factor for OS by multivariate analysis.

The expression level of mesothelin was evaluated if it could also be a prognostic factor for the PFS and OS of the advanced-stage EOC patients with or without optimal debulking surgery. The group of highly expressed mesothelin showed marginally shorter PFS (2.43 (0.99–5.95), \( P = 0.053 \)) and significantly worse OS (15.85 (1.76–125.6), \( P = 0.013 \)) as compared with that of low-expressed mesothelin in 44 patients in advanced-stage EOC with optimal debulking surgery (Figure 4A and B). The group of highly expressed mesothelin showed significantly shorter PFS (2.48 (1.44–4.27), \( P = 0.001 \)) and worse OS (4.47 (1.83–10.88), \( P = 0.001 \)) as compared with that of low-expressed mesothelin in 60 patients of advanced-stage EOC with suboptimal debulking surgery (Figure 4C and D).

**Figure 1** (A) Representative figure of quantification of mesothelin mRNA expression in tumour samples by RTQ RT–PCR. (B) Representative figure of quantification of G6PDH mRNA expression in tumour samples by RTQ RT–PCR. (C) Representative figure of mesothelin and GAPDH mRNA expressions by RT–PCR. (D) Correlation of mesothelin mRNA expression between RTQ RT–PCR and SQ RT–PCR (\( r = 0.334 \)).
Expression levels of mesothelin

 Persistent disease
[Recurrence (≤6 months)]
Recurrence (7–12 months)
Recurrence or no recurrence (7–12 months)

Figure 2 (A) Mesothelin mRNA expression levels between different stages of ovarian carcinoma. (B) The expression levels of chemosensitive and chemoresistant groups in 139 ovarian cancer patients with optimal (n = 78) and suboptimal (n = 61) debulking surgery. (C) Mesothelin mRNA expression levels in ovarian cancer patients with various progression-free intervals.

Table 3 Univariate and multivariate analyses of prognostic factors on the PFS of 139 ovarian epithelial carcinoma patients

| Univariate | Multivariate |
|------------|-------------|
| **Histology** | **Histology** |
| Serous/non-serous | 1.46 (0.91–2.35) | 0.12 |
| Stage | 1.84 (1.32–2.57) | <0.001 |
| III and IV/I and II | 1.38 (0.95–2.02) | 0.094 |
| Grade | 1.21 (0.95–1.54) | 0.12 |
| 3/1 and 2 | 2.36 (1.50–3.70) | <0.001 |
| Optimal debulking surgery | 1.37 (0.82–2.29) | 0.23 |
| Yes/No | 1.56 (0.83–2.92) | 0.17 |
| Lymph node metastasis | 1.34 (0.86–2.09) | 0.21 |
| CA125 levels >1000 U ml⁻¹ | 3.45 (2.17–5.47) | <0.001 |
| Time to normal CA125 level | 2.14 (1.28–3.58) | 0.004 |
| Longer/less than 63 days | 2.03 (1.23–3.37) | 0.006 |
| Mesothelin expression level | 2.63 (1.62–4.26) | <0.001 |
| Highly vs low | Abbreviations: CI = confidence interval; PFS = progression-free survival. *By Kaplan–Meier test. **Variable included in the multivariate model.
Table 4  Univariate and multivariate analyses of prognostic factors on the overall survival of 139 ovarian epithelial carcinoma patients

| Factor                              | Odds ratio (95% CI) | P-value* | Odds ratio (95% CI) | P-value* |
|-------------------------------------|---------------------|----------|---------------------|----------|
| Histology                           |                     |          |                     |          |
| Serous/non-serous                   | 1.25 (0.64–2.44)    | 0.51     |                     |          |
| Stage                               |                     |          |                     |          |
| III and IV/II and II                | 2.08 (1.24–3.50)    | 0.006    | 1.55 (0.86–2.82)    | 0.15     |
| Grade                              |                     |          |                     |          |
| 3/1 and 2                           | 1.04 (0.75–1.42)    | 0.83     |                     |          |
| Optimal debulking surgery           |                     |          |                     |          |
| No/yes                              | 3.35 (1.71–6.54)    | <0.001   | 1.88 (0.84–4.17)    | 0.12     |
| Lymph node metastasis               |                     |          |                     |          |
| Yes/no                              | 1.67 (0.62–4.49)    | 0.31     |                     |          |
| CA125 levels > 1000 U/ml           | 1.88 (0.97–3.63)    | 0.06     |                     |          |
| Time to normal CA125 level         |                     |          |                     |          |
| Longer/less than 63 days           | 3.41 (1.80–6.47)    | <0.001   | 1.93 (0.88–4.22)    | 0.099    |
| Mesothelin expression level         |                     |          |                     |          |
| High vs low                         | 4.64 (2.15–10.03)   | <0.001   | 3.72 (1.64–8.45)    | 0.002    |

Abbreviation: CI = confidence interval. *By Kaplan–Meier test. **Variable included in the multivariate model.

Figure 3  (A) The overall survival of 139 ovarian carcinoma patients with early and advanced stages (P = 0.006). (B) The OS of 139 ovarian carcinoma patients with optimal and suboptimal debulking surgery (P < 0.001). (C) The OS of 139 ovarian carcinoma patients with time to normal CA125 level less and longer than 63 days (P < 0.001). (D) The OS of 139 ovarian carcinoma patients with high- and low-expressed mesothelin levels (P < 0.001).
DISCUSSION

Mesothelin may be an emerging marker for diagnosis and target-based therapy in ovarian epithelial cancers. Ovarian cancer is one of the most common types of carcinoma that overexpresses mesothelin. Our SQ RT-PCR and QRT RT-PCR analyses confirmed earlier reports (Chang and Pastan, 1996; Schaner et al., 2003) that mesothelin was expressed in cancerous tissues of ovarian carcinomas, suggesting that mesothelin could be an ideal marker for cancer diagnosis and target-based therapy. Recently, several molecules other than mesothelin have been found to be potential biomarkers for ovarian carcinoma, such as DF3, vascular endothelial growth factor, MUC1, HE4, and CA19-9 (Cheng et al., 1999; Rosen et al., 2005; Heffer et al., 2006). Moore et al. (2008) also reported that combined CA125 and HE4 is a more accurate predictor of malignancy than either of them alone. The challenge is to conduct a prospective study using comprehensive gene expression analyses, including these potential biomarkers with sufficient patient numbers.

The first significant finding of this study is that mesothelin expression conferred a poorer chemoresponse in EOC patients. As the effect of cytotoxic drugs is influenced by histological stage and tumour volume, we analysed if the expression level of mesothelin could correlate with the chemoresponse of EOC patients with similar histological stages and residual tumour sizes. The expressions of mesothelin in chemo-sensitive EOC patients with residual tumour size \( \leq 1 \) or \( > 1 \) cm were significantly lower than those in the chemoresistant groups, which indicates that mesothelin can be a potential biomarker to evaluate chemotherapeutic effects on EOC patients.

Our findings imply that cancer cells containing greater levels of mesothelin can resist cytotoxic drug-induced apoptosis and will continue to progress, unlike other tumour cells that fail to express mesothelin. Mesothelin may have the function of regulating the traffic of molecules and cells into and out of the peritoneal cavity (Bera and Pastan, 2000). We hypothesise that mesothelin may alter the time spent by cytotoxic drugs in the peritoneal cavity, or change the tumour microenvironment of ovarian cancer patients so as to inhibit the effects of cytotoxic drugs. Nonetheless, other mechanisms may also exist although the major mechanisms of resistance that have been identified thus far involve reduced drug uptake, increased drug efflux, increased repair of platinum-DNA adducts, increased tolerance of DNA damage, and increased levels of intra-cellular thiols, such as glutathione and metallothionein.

**Figure 4** (A) The progression-free survival (PFS) of 44 advanced-stage ovarian cancer patients undergoing optimal debulking surgery with high- and low-expressed mesothelin \( P = 0.053 \). (B) The overall survival of 44 advanced-stage ovarian cancer patients undergoing optimal debulking surgery with high- and low-expressed mesothelin levels \( P = 0.013 \). (C) The PFS of 60 advanced-stage ovarian cancer patients undergoing suboptimal debulking surgery with high- and low-expressed mesothelin levels \( P = 0.001 \). (D) The OS of 60 advanced-stage ovarian cancer patients undergoing suboptimal debulking surgery with high- and low-expressed mesothelin levels \( P = 0.001 \).
Mesothelin with chemoresponsive of epithelial ovarian carcinoma
W-F Cheng et al

Biomarkers to predict the chemotherapeutic response have clinical significance in the management of EOC patients (Kupryjanczky et al, 2003; de Graeff et al, 2008). Adjuvant chemotherapy has improved disease-free intervals and OS in various malignancies. However, the treatment can still be viewed largely as a ‘shot in the dark’ and the tools available to help predict who will respond optimally to which treatment are still relatively crude. Some molecules, such as BRCA1 (Quinn et al, 2007), soluble Fas levels (Chaudhry et al, 2008), Death Receptor 4 and TNF receptor 2 (TNFR2) (Dong et al, 2008), EF24 (Selvendiran et al, 2007), and trophinin (Baba et al, 2007), have been shown to correlate with cisplatin resistance in human ovarian cancer. The molecular markers involved in the activity of chemotherapeutic agents can shed light on the successes and failures of treatment in ovarian cancer patients and can also provide a basis for individualised therapy.

The second significant finding of this study is that mesothelin expression confers poor clinical outcome in EOC patients. The correlation of mesothelin expression with several other clinicopathological features, including pathological stage, tumour grade, drug resistance status, and status of optimal surgery, indicates that mesothelin seems to be associated with these variables. The Kaplan–Meier analysis for 104 stage III–IV cases revealed that the PFS and OS of 33 patients of highly expressed mesothelin were 6 versus 15 months ($P = 0.026$) and 18 versus 28 months ($P = 0.008$), respectively. There was no significant difference between these groups in age, tumour histology, tumour debulking status, or chemotherapy regimens, which shows that mesothelin is over-expressed in tumours with worse outcome and is suggestive of its independently preventive role in ovarian tumour progression.

Shih and co-workers reported that high-grade ovarian serous adenocarcinoma patients with diffuse mesothelin staining had better median OS than those with negative or focal mesothelin staining by the distribution pattern of mesothelin (Yen et al, 2006). The mesothelin expression and OS of 59 ovarian high-grade serous adenocarcinoma were also analysed in this study. The 42 mesothelin highly expressed, high-grade serous adenocarcinoma patients showed a marginally shorter OS than did 17 mesothelin low-expressed patients (13 vs 34 months, $P = 0.055$). We also carried out immunostaining for some of our patients. Our results revealed that the expression of mesothelin had good correlations between the intensity of immunostaining and RTQ RT–PCR values (data not shown). RTQ RT–PCR method is more objective and sensitive to quantitate the amount of mesothelin expression than the immunostaining method, though this method cannot identify the exact cells that secrete mesothelin. It is interesting to evaluate the correlation between the expression levels of mesothelin and its distributing pattern.

Our study presenting mesothelin expression in ovarian carcinomas provides new evidence that a higher mesothelin expression is associated with chemoresistance in patients and shorter patient survival. Multi-institutional studies will be required to confirm whether mesothelin is a really independent predictor for chemotherapy in EOC patients. Future gene therapy directed towards enhancing mesothelin expression in cancer cells might offer a new treatment strategy for ovarian cancer patients.

ACKNOWLEDGEMENTS
This work was supported in part by the Department of Medical Research of NTUH and by grants from the National Science Committee of Taiwan (97-2314-B-002-064-MY3). The submitted article is an original work and has not been published before or under consideration by any other publication.

REFERENCES
Agarwal R, Kaye SB (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3: 502–516
Baba T, Mori S, Matsumura N, Kariya M, Murphy SK, Kondoh E, Kusakari T, Kuroda H, Mandai M, Higuchi T, Takakura K, Fukuda MN, Fujii S (2007) Trophinin is a potent prognostic marker of ovarian cancer involved in platinum sensitivity. Biochem Biophys Res Commun 360: 363–369
Beard CM, Hartmann LC, Atkinson EJ, O’Brien PC, Malkasian GD, Keeney GL, Melton III LJ (2000) The epidemiology of ovarian cancer: a population-based study in Olmsted County, Minnesota, 1935–1991. Ann Epidemiol 10: 14–23
Bera TK, Pastan I (2000) Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 20: 2902–2906
Boyle P, Maisonneuve P, Attier P (2000) Update on cancer control in women. Int J Gynaecol Obstet 70: 263–303
Bradshaw DM, Arcoci RJ (1998) Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 16: 3674–3690
Chang CL, Wu TC, Hung CF (2007) Control of human mesothelin-expressing tumors by DNA vaccines. Gene Therapy 14: 1189–1198
Chang K, Pastan I (1996) Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 93: 136–140
Chang K, Pastan I, Willingham MC (1992) Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 50: 373–381
Chaudhry P, Srinivasan R, Patel FD, Gopalan S, Majumdar S (2008) Serum soluble Fas levels and prediction of response to platinum-based chemotherapy in epithelial ovarian cancer. Int J Cancer 122: 1716–1721
Cheng WF, Chen CA, LEE CN, Chen TM, HSIEH FJ, HSIEH CY (1999) Vascular endothelial growth factor in cervical carcinoma. Obstet Gynecol 93: 761–765
Cheng WF, Hung CF, Chai CY, Chen CA, Lee CN, Su YN, Tseng WY, HSIEH CY, SHIH IE, WANG TL, Wu TC (2007) Generation and characterization of an ascitogenic mesothelin-expressing tumor model. Cancer 110: 420–431
de Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, Oen K, Bartlett JM, Wisman GB, de Bock GH, de Vries EG, de Jong S, van der Zee AG (2008) The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer 99: 341–349
DiSaia PJ, Blass JD (2003) Treatment of ovarian cancer: new strategies. Gynecol Oncol 90: S24–S32
Dong HP, Kleinberg L, Silins I, Floresen VA, Trope CG, Riebg P, Nesland JM, Davidson B (2008) Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma. Cancer 112: 84–93
Fan D, Yano S, Shinohara H, Solorzano C, Van Arsdall M, Bucana CD, Pathak S, Kruzel E, Herbst RS, Onn A, ROACH JS, ONDA M, WANG QC, Pastan I, Fidler HJ (2002) Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. Mol Cancer Ther 1: 595–600
Gonzalez-Diego P, Lopez-Abente G, Pollan M, Ruiz M (2000) Time trends in cervical cancer mortality in Europe (1955–1993). Effect of age, birth cohort and period of death (in process citation). Eur J Cancer 36: 1816–1824
Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics, 2001. CA Cancer J Clin 51: 15–36
Haq R, Banke B (1998) Inhibition of apoptotic signaling pathways in cancer cells as a mechanism of chemotherapy resistance. Cancer Metastasis Rev 17: 233–239
Hassan R, Bullock S, Premkumar A, Kreitman BJ, Kindler H, Willingham MC, Pastan I (2007a) Phase I study of SSIP, a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Cln Cancer Res 13: 5144–5149
Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin E, Gibbs L, Phillips MD, Mudali S, Iacobuzio-Donahue C,
Jaffee EM, Moreno M, Pastan I, Sass PM, Niculaides NC, Grasso L (2007b) Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. *Cancer Immunol Ther* 20–29

Heller LA, Zeilinger R, Grimm C, Sood AK, Cheng WF, Gadducci A, Tempfer CB, Reinthaller A (2006) Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. *Gynecol Oncol* 103: 512–517

Huang CY, Cheng WF, Lee CN, Su YN, Chien SC, Tzeng YL, Hsieh CY, Chen CA (2006) Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. *Anticancer Res* 26: 4721–4728

Kupryjanczyk J, Szymanska T, Madry R, Timorek A, Stelmachow J, Karpinska G, Rembiszewska A, Ziolkowska I, Kraszewska E, Debniak J, Emerich J, Ulanska M, Pluzanska A, Jedryka M, Goluda M, Chudecka-Glaz A, Rzepka-Gorska I, Klimek M, Urbanski K, Breborowicz J, Zielinski J, Markowska I (2003) Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. *Br J Cancer* 88: 848–854

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402–408

Masson S, Daveau M, Francois A, Bodenat C, Hiron M, Teniere P, Salier JP, Scotte M (2001) Up-regulated expression of HGF in rat liver cells after experimental endotoxemia: a potential pathway for enhancement of liver regeneration. *Growth Factors* 18: 237–250

Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast Jr RC (2008) The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. *Gynecol Oncol* 108: 402–408

Ozols RF (2002) Update on the management of ovarian cancer. *Cancer J* 8(Suppl 1): S22–S30

Parkin DM, Pisani P, Ferlay J (1993) Estimates of the worldwide incidence of eighteen major cancers in 1985. *Int J Cancer* 54: 594–606

Pfeiferer A (1984) Diagnosis and staging of ovarian cancer. *J Cancer Res Clin Oncol* 107: 81–88

Quinn JE, James CR, Stewart GE, Mulligan JM, White P, Chang GK, Mullan PB, Johnston PG, Wilson RH, Harkin DP (2007) BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. *Clin Cancer Res* 13: 7413–7420

Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast Jr RC (2005) Potential markers that complement expression of CA125 in epithelial ovarian cancer. *Gynecol Oncol* 99: 267–277

Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A (2004) Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. *J Biol Chem* 279: 9190–9198

Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, Mitchell H, Lambert HE (1996) Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. *J Clin Oncol* 14: 1545–1551

Schauer ME, Ross DT, Ciaramino G, Sorlie T, Troyanskaya O, Diehm N, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu IP, Hernandez-Boussard T, Johnson SW, O'Dwyer PJ, Fero MJ, Kristensen GB, Borresen-Dale AL, Hastie T, Tibshirani R, van de Rijn M, Teng NN, Longacre TA, Botstein D, Brown PO, Sikic BI (2003) Gene expression patterns in ovarian carcinomas. *Mol Biol Cell* 14: 4376–4386

Schwartz PE (2003) Diagnosis and treatment of epithelial ovarian cancer. *Minerva Ginecol* 55: 315–326

Selvendiran K, Tong L, Vishwanath S, Bratasz A, Trigg NJ, Kutala VK, Hideg K, Kuppusamy P (2007) EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. *J Biol Chem* 282: 28609–28618

Sobin LH, Fleming ID (1997) TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. *Cancer* 80: 1803–1804

Stuart GC (2003) First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. *Gynecol Oncol* 90: S8–S15

Yen MJ, Hsu CY, Mao TL, Wu TC, Roden R, Wang TL, Shih IeM (2006) Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. *Clin Cancer Res* 12: 827–831

© 2009 Cancer Research UK

British Journal of Cancer (2009) 100(7), 1144–1153